Leslie D. Funtleyder - 19 Dec 2025 Form 4 Insider Report for Applied Therapeutics, Inc. (APLT)

Role
Chief Financial Officer, Director
Signature
/s/ Leslie D. Funtleyder
Issuer symbol
APLT
Transactions as of
19 Dec 2025
Net transactions value
$0
Form type
4
Filing time
03 Feb 2026, 18:47:47 UTC
Previous filing
19 Dec 2025
Next filing
02 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Funtleyder Leslie D. Chief Financial Officer, Director C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK /s/ Leslie D. Funtleyder 03 Feb 2026 0001775394

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLT Common Stock Award $0 +1,187,500 +89% $0.000000 2,527,959 19 Dec 2025 Direct F1
transaction APLT Common Stock Disposed to Issuer -2,375,000 -94% 152,959 03 Feb 2026 Direct F2, F3
transaction APLT Common Stock Disposition pursuant to a tender of shares in a change of control transaction -152,959 -100% 0 03 Feb 2026 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLT Stock Option (Right to Buy) Disposed to Issuer -20,460 -100% 0 03 Feb 2026 Common Stock 20,460 $1.05 Direct F5
transaction APLT Stock Option (Right to Buy) Disposed to Issuer -10,230 -100% 0 03 Feb 2026 Common Stock 10,230 $1.05 Direct F5
transaction APLT Stock Option (Right to Buy) Disposed to Issuer -16,500 -100% 0 03 Feb 2026 Common Stock 16,500 $1.05 Direct F5
transaction APLT Stock Option (Right to Buy) Disposed to Issuer -16,500 -100% 0 03 Feb 2026 Common Stock 16,500 $1.05 Direct F5
transaction APLT Stock Option (Right to Buy) Disposed to Issuer -150,000 -100% 0 03 Feb 2026 Common Stock 150,000 $1.02 Direct F5
transaction APLT Stock Option (Right to Buy) Disposed to Issuer -40,502 -100% 0 03 Feb 2026 Common Stock 40,502 $4.70 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Leslie D. Funtleyder is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in full upon the earlier of (i) the consummation of a Change in Control (as defined in the Plan) or (ii) June 19, 2026, in each case, subject to the Reporting Person continuing to provide services through each such date.
F2 Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration").
F3 Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration.
F4 Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration.
F5 Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

Remarks:

Interim Chief Executive Officer and Chief Financial Officer